Cargando…

Combination of GLP‐1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study

AIMS: Intensification of type 2 diabetes (T2DM) treatment with GLP‐1 receptor agonists (GLP‐1RAs) promotes weight loss. We aimed to determine the synergistic effect of behavioural programmes on body weight on top of GLP‐1RA treatment. MATERIALS AND METHODS: We retrospectively analysed the time cours...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petroni, Maria Letizia, Montesi, Luca, Colosimo, Santo, Caletti, Maria Turchese, Mazzotti, Arianna, Marchesini, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775466/ https://www.ncbi.nlm.nih.gov/pubmed/31592154 http://dx.doi.org/10.1002/edm2.82

Ejemplares similares

Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery
por: Di Luzio, Raffaella, et al.
Publicado: (2020)

Emergency department accesses for diabetes-related complications during COVID-19 pandemic in people with type 2 diabetes and depression
por: Messina, Rossella, et al.
Publicado: (2022)

Prevention and Treatment of Sarcopenic Obesity in Women
por: Petroni, Maria L., et al.
Publicado: (2019)

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
por: Colosimo, Santo, et al.
Publicado: (2021)

Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women
por: Dalle Grave, Riccardo, et al.
Publicado: (2015)

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
por: Panfili, Eleonora, et al.
Publicado: (2023)

Long-term weight loss maintenance for obesity: a multidisciplinary approach
por: Montesi, Luca, et al.
Publicado: (2016)

Removal of Duodenum Elicits GLP-1 Secretion
por: Muscogiuri, Giovanna, et al.
Publicado: (2013)

The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention
por: Zhu, Boheng, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

443. Do people living with HIV lose weight on GLP-1 agonist therapy?
por: Tauhid, Lamiya, et al.
Publicado: (2022)

1982. GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV
por: Nguyen, Quynh P, et al.
Publicado: (2023)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs
por: Petroni, Maria Letizia, et al.
Publicado: (2023)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

The Effect of Lutein on Eye and Extra-Eye Health
por: Buscemi, Silvio, et al.
Publicado: (2018)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vrqc2aa6rpria0c986bvv0pib